KD Pharma Group
- Company typePrivate
- Founded1981
- HeadquartersBioggio, Switzerland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
KD Pharma Group firmographics
Firmographics- Name
- KD Pharma Group
- Legal name
- KD Pharma Group SA
- Website
- https://kdpharmagroup.com
- Company type
- Private
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
KD Pharma Group industry classification
Industry- Product category
- Pharmaceutical CDMO
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where KD Pharma Group is headquartered
LocationHeadquarters
- HQ city
- Bioggio
- HQ country
- Switzerland
- HQ region
- Europe
Offices8 records
Markets served
KD Pharma Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Organization (CDMO) Services: KD Pharma Group operates as a pure-play technology-driven CDMO providing vertically integrated manufacturing services across lipids and small molecules. Revenue is generated through custom synthesis, API manufacturing, and finished dosage form services for pharmaceutical and nutraceutical customers. Services span from R&D development through pilot plant cGMP for clinical supplies to large-scale commercial cGMP production.
- Omega-3 API and Ingredient Sales: Sale of pharmaceutical-grade Omega-3 APIs and concentrated ingredients to pharmaceutical and nutraceutical companies. The company supplies bulk API oil as well as bulk softgel capsules to major Omega-3 pharmaceutical markets including USA, EU, Korea and Japan.
- Finished Dosage Form Manufacturing: Manufacturing and sale of finished products including softgels, liquid solutions, and packaging services for nutritional market customers. Turnkey solutions from ingredient through finished packaged product.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
KD Pharma Group product offering
Product offeringCore offering
KD Pharma Group is a pure-play, technology-driven Contract Development and Manufacturing Organization (CDMO) that delivers vertically integrated services and products for pharmaceutical and nutraceutical customers, spanning lipid-based APIs and ingredients (especially omega-3 fish and algae oils up to 99% purity), custom synthesis of small molecule intermediates and APIs, finished dosage form manufacturing (softgels, liquids, emulsions, bottling and packaging), and independent lipid analytical laboratory services through KD LabService.
Product overview
KD Pharma Group is a technology-driven Contract Development and Manufacturing Organization (CDMO) offering vertically integrated pharmaceutical and nutraceutical solutions. The company operates across three core technology platforms: kd-pür® extraction and purification technologies (including Supercritical Fluid Extraction, Supercritical Fluid Chromatography, Enhanced Silver Technology, and Simulated Moving Bed chromatography), synthesis technologies (high pressure reactions, cryogenic chemistry, chiral separations), and Innovagel® softgel technologies. Product portfolio includes Omega-3 APIs and concentrates up to 99% purity (fish and algae-based via Alga3™ brand), custom synthesis of pharmaceutical intermediates and APIs, finished dosage forms (softgels, liquids, emulsions), KD LabService™ independent lipid analysis laboratory, KD Phyto™ cannabinoid products, and branded formulations like Move3® joint health and ReGen3™ omega-3. Recent acquisition of dsm-firmenich's MEG-3® fish oil business expanded manufacturing footprint and product range. KD Pharma serves pharmaceutical, nutritional supplement, and specialty chemical markets with facilities in Germany, Norway, UK, Canada, Peru, USA, and Switzerland.
Differentiator
Problem solved
Functional benefit
Brands
- OceanBlue: Nutritional consumer brand owned by KD Pharma Group providing data on consumer perceptions of KD Nutra Omega-3 solutions.
- MEG-3
- Alga3
- kd-pur
- Innovagel
- ReGen3
- Kardio3
- Move3
- EPAspire
Products and services
- Custom Synthesis Services Full spectrum drug substance CDMO services from R&D development through pilot plant cGMP for clinical supplies to large-scale commercial cGMP production of APIs, intermediates, and specialty chemicals. Includes high pressure reactions (H2, CO2, CO, NH3), cryogenic chemistry down to -90°C, and chiral separations via SMB chromatography. Targets pharmaceutical companies needing complex multi-step synthesis.
- Omega-3 APIs and Concentrates Pharmaceutical and nutraceutical-grade omega-3 APIs and concentrates in fish oil and algae-based varieties, available in purity levels up to 99% from cGMP manufacturing facilities. Supplied as bulk API oil and bulk softgel capsules to major Omega-3 pharmaceutical markets including USA, EU, Korea and Japan.
- Finished Dosage Forms Turnkey softgel, liquid, and emulsion manufacturing services including formulation development, encapsulation processing (size 2 oval to size 28 oblong), bottling, and packaging for nutritional and pharmaceutical products. Backed by the Miami softgel center of excellence with capacity of 2 billion softgels per year across 7 encapsulation production lines.
- KD LabService Independent contract lipid analysis laboratory providing highly accurate testing services for omega-3 oils under cGMP conditions, offering titration, GC, HPLC, UV/FTIR, and physical analysis methods. ISO 17025:2018 certified. Recipient of GOED Special Achievement Program recognition in 2024 and 2025-2026.
- KD Phyto Cannabinoid APIs Cannabinoid business unit manufacturing pharmaceutical-grade CBD and other cannabinoid Active Pharmaceutical Ingredients (APIs) using proprietary lipid extraction and purification technologies. Includes 51% stake in Trigal Pharma which distributes CBD API through magistral preparations channel in Austria and Germany.
- Alga3 Vegan Omega-3 Platform Sustainable vegan omega-3 platform delivering microalgae-derived oils with customizable EPA:DHA ratios up to 95% concentration, providing plant-based alternatives to fish oil products. V-Label Vegan certified at Bexbach, Germany.
- Move3 Joint Health Formula Joint health formula combining kd-pur omega-3 fish oil with NEM (Natural Eggshell Membrane) eggshell membrane, clinically proven to reduce joint pain, stiffness and cartilage degradation in healthy adults. Developed in global exclusive partnership with Stratum Nutrition.
- EPAspire Drug Candidate Novel oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules, in Phase 3 clinical trials for Familial Adenomatous Polyposis (FAP), Ulcerative Colitis, and COVID-19 treatment. Developed in partnership with SLA Pharma. MHRA approved trial with FDA application submitted.
- ReGen3 Next-Generation Omega-3 Next-generation omega-3 concentrate with enriched pre-resolving mediators (PRMs) offering enhanced anti-inflammatory and resolution benefits compared to standard EPA and DHA products.
- MEG-3 Fish Oil Omega-3 Brand Premium fish oil omega-3 brand acquired from dsm-firmenich as part of the Marine Lipids business, covering food, beverage, dietary supplement and pharmaceutical applications globally.
Quantifiable outcome
- 60-75% reduction in CO2 emissions at German production sites
- +2 more outcomes
Companies that use KD Pharma Group
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
KD Pharma Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
KD Pharma Group partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- dsm-firmenichcoreKD Swiss GmbH signed agreement to acquire the distribution and supply of the food-grade oil business from dsm-firmenich. Acquisition financed by shareholder loan. Closing expected without conditions precedent.
- dsm-firmenichcoreKD Pharma Group completed acquisition of dsm-firmenich's Marine Lipids business including MEG-3® brand and production facilities in Peru and Canada. In return, dsm-firmenich received a minority stake in the enlarged KD group. This transaction positions KD Pharma as the largest omega-3 manufacturer in the world.
- GOED (Global Organization for EPA and DHA Omega-3s)minorKD LabService received GOED Special Achievement Program recognition for excellence in AOCS Laboratory Proficiency Program for omega-3 analysis. GOED promotes omega-3 education and standards across the industry.
- Trigal PharmacoreKD Pharma Group acquired 51% stake in Trigal Pharma, a company specialized in clinical research, development and marketing of medical cannabinoids including Cannabidiol (CBD) in highly-purified form. Trigal manufactures and distributes CBD API through magistral preparations channel in Austria and Germany.
- Stratum NutritioncoreGlobal exclusive partnership to develop MOVE3® combining Stratum's NEM® brand eggshell membrane and KD Pharma's kd-pür® marine omega oils. Product marketed in softgels via both companies' global sales forces. Published clinical study showing significant reductions in joint pain and stiffness.
- SLA PharmacorePartnership for development of EPAspire™ drug candidate entering clinical trials for COVID-19 treatment. SLA Pharma leads clinical development while KD Pharma provides highly purified EPA-FFA formulation. MHRA approved trial with discussions ongoing in other European countries and FDA application submitted.
Scale indicators8 records
Recent moves10 records
Expansion highlights6 records
KD Pharma Group competitors and assessment
Company assessmentMarket position
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
KD Pharma Group social profiles
Digital presenceKD Pharma Group compliance and trust
Trust signalCompliance14 records
KD Pharma Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
KD Pharma Group leadership team
Management profileNumber of profiles
Profiles11 records
KD Pharma Group subsidiaries and ownership
Company hierarchySubsidiaries11 records
KD Pharma Group funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KD Pharma Group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KD Pharma Group
What does KD Pharma Group do?
KD Pharma Group is a pure-play, technology-driven Contract Development and Manufacturing Organization (CDMO) that delivers vertically integrated services and products for pharmaceutical and nutraceutical customers, spanning lipid-based APIs and ingredients (especially omega-3 fish and algae oils up to 99% purity), custom synthesis of small molecule intermediates and APIs, finished dosage form manufacturing (softgels, liquids, emulsions, bottling and packaging), and independent lipid analytical laboratory services through KD LabService.
Is KD Pharma Group a public or private company?
KD Pharma Group is a private company. It is classified as private equity controlled and is currently operating.
When was KD Pharma Group founded?
KD Pharma Group was founded in 1981. It employs 251 to 500 people.
Where is KD Pharma Group based?
KD Pharma Group is headquartered in Bioggio, Switzerland, in the Europe region.
How does KD Pharma Group make money?
Three revenue lines are on record. Contract Development and Manufacturing Organization (CDMO) Services are the primary driver. The others are omega-3 API and Ingredient Sales and finished Dosage Form Manufacturing.
Does KD Pharma Group have an API?
No public API is recorded for KD Pharma Group.
What industry is KD Pharma Group in?
KD Pharma Group's product category is Pharmaceutical CDMO. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 325412 and its SIC code is 2834.